Keyword search (4,164 papers available)

"Neurodegenerative disease" Keyword-tagged Publications:

Title Authors PubMed ID
1 Exploring neurologists perspectives: barriers and facilitators in implementing cognitive care planning Ge S; Xiao X; Huang B; Britt KC; 41163714
CONCORDIA
2 In vitro evaluation of isatin-pyridine oxime hybrids as potential acetylcholinesterase inhibitors for nerve agent prophylaxis Silva MCJD; Pinto AMV; Balthar MA; Correa ABA; Bhattacharyya D; Simas ABC; Kuca K; Forgione P; França TCC; Cavalcante SFA; Kitagawa DAS; 40516590
CHEMBIOCHEM
3 Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders Eskandari K; Bélanger SM; Lachance V; Kourrich S; 40430519
CSBN
4 Microglial senescence in neurodegeneration: Insights, implications, and therapeutic opportunities Samuel Olajide T; Oyerinde TO; Omotosho OI; Okeowo OM; Olajide OJ; Ijomone OM; 39364217
PSYCHOLOGY
5 Measures of motor segmentation from rapid isometric force pulses are reliable and differentiate Parkinson's disease from age-related slowing Howard SL; Grenet D; Bellumori M; Knight CA; 35768733
PSYCHOLOGY
6 Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study. Pieruccini-Faria F, Black SE, Masellis M, Smith EE, Almeida QJ, Li KZH, Bherer L, Camicioli R, Montero-Odasso M 33590967
PSYCHOLOGY
7 Consensus on Shared Measures of Mobility and Cognition: From the Canadian Consortium on Neurodegeneration in Aging (CCNA). Montero-Odasso M, Almeida QJ, Bherer L, Burhan AM, Camicioli R, Doyon J, Fraser S, Muir-Hunter S, Li KZH, Liu-Ambrose T, McIlroy W, Middleton L, Morais JA, Sakurai R, Speechley M, Vasudev A, Beauchet O, Hausdorff JM, Rosano C, Studenski S, Verghese J, Canadian Gait and Cognition Network 30101279
PERFORM

 

Title:Microglial senescence in neurodegeneration: Insights, implications, and therapeutic opportunities
Authors:Samuel Olajide TOyerinde TOOmotosho OIOkeowo OMOlajide OJIjomone OM
Link:https://pubmed.ncbi.nlm.nih.gov/39364217/
DOI:10.1002/nep3.56
Publication:Neuroprotection
Keywords:agingferritinmicroglianeurodegenerative diseasessenescence-associated secretory phenotypesenescent
PMID:39364217 Category: Date Added:2024-10-04
Dept Affiliation: PSYCHOLOGY
1 Laboratory for Experimental and Translational Neurobiology, University of Medical Sciences, Ondo, Ondo, Nigeria.
2 Department of Physiology, School of Basic Medical Science, Federal University of Technology, Akure, Ondo, Nigeria.
3 Center for Studies in Behavioral Neurobiology, Department of Psychology, Concordia University, Montreal, Quebec, Canada.
4 Division of Neurobiology, Department of Anatomy, Faculty of Basic Medical Sciences, University of Ilorin, Ilorin, Kwara, Nigeria.
5 Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA.

Description:

The existing literature on neurodegenerative diseases (NDDs) reveals a common pathological feature: the accumulation of misfolded proteins. However, the heterogeneity in disease onset mechanisms and the specific brain regions affected complicates the understanding of the diverse clinical manifestations of individual NDDs. Dementia, a hallmark symptom across various NDDs, serves as a multifaceted denominator, contributing to the clinical manifestations of these disorders. There is a compelling hypothesis that therapeutic strategies capable of mitigating misfolded protein accumulation and disrupting ongoing pathogenic processes may slow or even halt disease progression. Recent research has linked disease-associated microglia to their transition into a senescent state-characterized by irreversible cell cycle arrest-in aging populations and NDDs. Although senescent microglia are consistently observed in NDDs, few studies have utilized animal models to explore their role in disease pathology. Emerging evidence from experimental rat models suggests that disease-associated microglia exhibit characteristics of senescence, indicating that deeper exploration of microglial senescence could enhance our understanding of NDD pathogenesis and reveal novel therapeutic targets. This review underscores the importance of investigating microglial senescence and its potential contributions to the pathophysiology of NDDs, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Additionally, it highlights the potential of targeting microglial senescence through iron chelation and senolytic therapies as innovative approaches for treating age-related NDDs.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University